These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37012321)

  • 21. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer.
    Lampropoulou DI; Aravantinos G; Katifelis H; Lazaris F; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M
    Cancer Biomark; 2019; 25(2):213-221. PubMed ID: 31045514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.
    Saeki H; Emi Y; Kumashiro R; Otsu H; Kawano H; Ando K; Ida S; Kimura Y; Tokunaga E; Oki E; Morita M; Shimokawa M; Maehara Y
    Surg Today; 2014 Aug; 44(8):1457-64. PubMed ID: 24013837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
    J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer.
    Abdallah EA; Fanelli MF; Souza E Silva V; Machado Netto MC; Gasparini Junior JL; Araújo DV; Ocea LM; Buim ME; Tariki MS; Alves Vda S; Piana de Andrade V; Dettino AL; Abdon Lopes de Mello C; Chinen LT
    Int J Cancer; 2016 Aug; 139(4):890-8. PubMed ID: 26950035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.
    Lehtomaki KI; Lahtinen LI; Rintanen N; Kuopio T; Kholova I; Makela R; Rantala JK; Kellokumpu-Lehtinen PL; Kononen J
    Anticancer Res; 2019 Nov; 39(11):5867-5877. PubMed ID: 31704811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revisiting the frontiers of pharmacogenomics of colon cancer.
    Falandry C; Bonnefoy M; Freyer G
    Pharmacogenomics; 2011 Sep; 12(9):1243-8. PubMed ID: 21919602
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
    Goldberg R
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
    [No Abstract]   [Full Text] [Related]  

  • 29. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.
    Caputo F; Santini C; Bardasi C; Cerma K; Casadei-Gardini A; Spallanzani A; Andrikou K; Cascinu S; Gelsomino F
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
    Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
    Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
    Tong M; Zheng W; Lu X; Ao L; Li X; Guan Q; Cai H; Li M; Yan H; Guo Y; Chi P; Guo Z
    Oncotarget; 2015 Dec; 6(38):41216-27. PubMed ID: 26515599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvements in Clinical Outcomes for
    Morris VK; Bekaii-Saab T
    Clin Cancer Res; 2020 Sep; 26(17):4435-4441. PubMed ID: 32253230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
    Jeong WJ; Cha PH; Choi KY
    World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
    Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
    Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
    Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
    Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
    Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer.
    Reynolds IS; O'Connell E; Fichtner M; McNamara DA; Kay EW; Prehn JHM; Furney SJ; Burke JP
    Pharmacogenomics J; 2020 Jun; 20(3):524-532. PubMed ID: 31819162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.